These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 34565068)

  • 1. Management of antithrombotic therapy in patients with atrial fibrillation and acute coronary syndromes.
    Pop C; Țînț D; Petris A
    Rev Cardiovasc Med; 2021 Sep; 22(3):659-675. PubMed ID: 34565068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
    Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Fanaroff AC; Lopes RD
    Prog Cardiovasc Dis; 2021; 69():11-17. PubMed ID: 34883097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients.
    Galli M; Andreotti F; Porto I; Crea F
    Europace; 2020 Apr; 22(4):538-546. PubMed ID: 31942971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis.
    Haller PM; Sulzgruber P; Kaufmann C; Geelhoed B; Tamargo J; Wassmann S; Schnabel RB; Westermann D; Huber K; Niessner A; Gremmel T
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):226-236. PubMed ID: 31198930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials.
    Potpara TS; Mujovic N; Proietti M; Dagres N; Hindricks G; Collet JP; Valgimigli M; Heidbuchel H; Lip GYH
    Europace; 2020 Jan; 22(1):33-46. PubMed ID: 31603196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.
    Angiolillo DJ; Goodman SG; Bhatt DL; Eikelboom JW; Price MJ; Moliterno DJ; Cannon CP; Tanguay JF; Granger CB; Mauri L; Holmes DR; Gibson CM; Faxon DP
    Circulation; 2018 Jul; 138(5):527-536. PubMed ID: 30571525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of the optimal antithrombotic treatment for acute coronary syndrome patients with concomitant atrial fibrillation and implanted with new-generation drug-eluting stent: OPtimal management of anTIthroMbotic Agents (OPTIMA)-4 trial.
    Gong X; Hua R; Bai J; Wu T; Wang Q; Zhang J; Zhang W; Ying L; Ke Y; Wang X; Zhang X; Liu K; Chen Y; Zhang B; Dong P; Xiao J; Li C; Zhu L; Li C
    Clin Cardiol; 2023 Jul; 46(7):777-784. PubMed ID: 37191146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic therapies in Canadian atrial fibrillation patients with concomitant coronary artery disease: Insights from the CONNECT AF + PCI-II program.
    Chow JK; Bagai A; Tan MK; Har BJ; Yip AMC; Paniagua M; Elbarouni B; Bainey KR; Paradis JM; Maranda R; Cantor WJ; Eisenberg MJ; Dery JP; Madan M; Cieza T; Matteau A; Roth S; Lavi S; Glanz A; Gao D; Tahiliani R; Welsh RC; Kim HH; Robinson SD; Daneault B; Chong AY; Le May MR; Ahooja V; Gregoire JC; Nadeau PL; Laksman Z; Heilbron B; Yung D; Minhas K; Bourgeois R; Overgaard CB; Bonakdar H; Logsetty G; Lavoie AJ; De LaRochelliere R; Mansour S; Spindler C; Yan AT; Goodman SG;
    J Cardiol; 2023 Aug; 82(2):153-161. PubMed ID: 36931433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
    Gargiulo G; Cannon CP; Gibson CM; Goette A; Lopes RD; Oldgren J; Korjian S; Windecker S; Esposito G; Vranckx P; Valgimigli M
    Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f50-f60. PubMed ID: 33119069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Sullivan AE; Nanna MG; Rao SV; Cantrell S; Gibson CM; Verheugt FWA; Peterson ED; Lopes RD; Alexander JH; Granger CB; Yee MK; Kong DF
    Catheter Cardiovasc Interv; 2020 Aug; 96(2):E102-E109. PubMed ID: 31713326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic therapy in coronary artery disease patients with atrial fibrillation.
    Wei L; Su E; Liu W; Xing W; Liu X; Zhang Y; Wang S; Cheng Q; Qi D; Gao C
    BMC Cardiovasc Disord; 2020 Jul; 20(1):323. PubMed ID: 32631244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a Role for Oral Triple Therapy in Patients with Acute Coronary Syndromes Without Atrial Fibrillation?
    Spinthakis N; Farag M; Akhtar Z; Gorog DA
    Curr Vasc Pharmacol; 2018; 16(5):427-436. PubMed ID: 29345587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
    Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Lamberts M; Gislason GH; Olesen JB; Kristensen SL; Schjerning Olsen AM; Mikkelsen A; Christensen CB; Lip GY; Køber L; Torp-Pedersen C; Hansen ML
    J Am Coll Cardiol; 2013 Sep; 62(11):981-9. PubMed ID: 23747760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting.
    Reed GW; Cannon CP
    Clin Cardiol; 2013 Oct; 36(10):585-94. PubMed ID: 23873635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and / or undergoing percutaneous coronary intervention.
    Mihajlovic M; Marinkovic M; Kozieł M; Mujovic N; Lip GYH; Potpara TS
    Kardiol Pol; 2020 Jun; 78(6):512-519. PubMed ID: 32543800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Saito Y; Kobayashi Y
    J Cardiol; 2019 Jan; 73(1):1-6. PubMed ID: 30293674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
    Xanthopoulou I; Dragona VM; Davlouros P; Tsioufis C; Iliodromitis E; Alexopoulos D;
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):191-196. PubMed ID: 29679301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.